Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy

Affiliations

Comment

Ashish Sharma et al. JAMA Ophthalmol. 2021.

. 2021 Jun 1;139(6):677-679.

doi: 10.1001/jamaophthalmol.2021.1037.

¹ Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, India.

No abstract available

Comment in

Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy-Reply.
Bressler NM. Bressler NM. JAMA Ophthalmol. 2021 Jun 1;139(6):678-679. doi: 10.1001/jamaophthalmol.2021.1043. JAMA Ophthalmol. 2021. PMID: 33914021 No abstract available.

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM. Woo SJ, et al. JAMA Ophthalmol. 2021 Jan 1;139(1):68-76. doi: 10.1001/jamaophthalmol.2020.5053. JAMA Ophthalmol. 2021. PMID: 33211076 Free PMC article. Clinical Trial.